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Conclusions: P16 is not a useful predictor of malignant transfor-
mation or recurrent disease and does not correlate well with previ-
ously validated epithelial proliferative markers in oral dysplasia.
doi:10.1016/j.oraloncology.2011.06.366
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Introduction: The phosphatidylinositol 3-kinase (PI3K) signaling
pathway is integral to cell growth, proliferation and survival, and is
upregulated in multiple human cancers. Several oncogenes and tu-
mor suppressors within this pathway are altered by mutation,
ampliﬁcation or deletion, and are currently being investigated as
therapeutic targets in ongoing clinical trials for head and neck and
other solid cancers. The pattern of genetic alteration has not been
characterized in oral cavity squamous cell carcinoma (OCSCC).
Objective: Our objective was to comprehensively analyze the
pattern of mutational and copy number alteration in this pathway
in OCSCC.
Methods: After IRB approval, DNA was extracted from 32 micro-
dissected frozen OCSCC samples and matched normal tissues. High-
throughput sequencing of 25 component genes of the PI3K pathway
was performed. Three integrated sequence assemblies were screened
for non-polymorphism coding mutations, which were independently
validated on PCR. Array comparative genomic hybridization (aCGH)
was then performed on the Agilent 1 M platform. The RAE computa-
tional framework was used for segmentation and identiﬁcation of re-
gions of statistically signiﬁcant copy number alteration (CNA), which
were then validated with qPCR. Immunohistochemistry of down-
stream proteins was used to conﬁrm pathway activation.
Results: Among the 25 component genes in the PI3K pathway,
activating mutations were identiﬁed in PIK3CA in 6.3% of samples.
Copy number gain was present in 15 genes (including PIK3CA in
45.2%), and loss in 4 genes (including PTEN in 12.9%). Altogether,
74% of tumor samples contained either activating mutations or CNAs
within the PI3K pathway. Tumors with PIK3CA mutation or EGFR
ampliﬁcation had a signiﬁcantly higher rate of copy number altera-
tions in the PI3K pathway.
Conclusions: In the ﬁrst comprehensive mutational and copy
number analysis of the 25 component genes of the PI3K pathway
in cancer, we report a low frequency of somatic mutations, and high
frequency of copy number alteration, in OCSCC. In contrast to colo-
rectal, breast, ovarian, and brain cancers, copy number alteration,
not mutation, appears to be the main source of pathway activation.
These ﬁndings may have relevance to therapeutics targeting tumors
in which the PI3K pathway is dysregulated, or in which PI3K path-
way activation mediates resistance to EGFR inhibition.
doi:10.1016/j.oraloncology.2011.06.367
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Background: Midkine is overexpressed in many carcinomas and
thought to play an important role in carcinogenesis. However, few
studies have been focused on the role of midkine in head and neck
squamous cell carcinoma.
Methods: Midkine expression status was analyzed by semi-
quantitative reverse transcriptase polymerase (RT-PCR), Western
blot and immunohistochemistry. Clinical parameters were obtained
from the medical records.
Result: Midkine is up-regulated in HNSCC, as evaluated by semi-
quantitative RT-PCR, Western blot, and immunohistochemistry. Po-
sitive staining for midkine is signiﬁcantly correlated with lymph
node metastasis, and has poorer ﬁve-year overall survival rate
(p = 0.008). Multivariate analysis revealed that midkine expression
was an independent prognostic factor (p = 0.002).
Conclusion: This is a report of an association between midkine
expression and all sites of HNSCC. Midkine may play an important
role in the progression of HNSCC, and evaluation of midkine expres-
sion is a useful prognostic factor among patients with HNSCC.
doi:10.1016/j.oraloncology.2011.06.368
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Introduction: The variability of clinical outcomes in oral cancer
patients and the heterogeneity of the disease are the main chal-
lenges for the improvement of current treatment modalities. Ef-
forts in our laboratory have focused on the molecular proﬁling
of oral cancer to understand the mechanisms underlying the dis-
ease. In a previous microarray study, we found Guanine nucleotide
binding protein alpha-12 (GNA12) to be up-regulated in oral
cancer.
Materials and methods: In this study, we validated the expres-
sion of GNA12 at the mRNA level in 47 oral squamous cell carcinoma
(OSCC) and 18 non-malignant oral mucosa tissues, by quantitative
polymerase chain reaction (qPCR). Further, GNA12 protein expres-
sion was accessed by immunohistochemistry (IHC) on 44 tumors
and 23 non-malignant oral mucosa tissues. Using OSCC cell lines,
we examined the effects of GNA12 signaling by in vitro functional
assays.
Results: We demonstrated that GNA12 mRNA levels were signif-
icantly up-regulated in OSCC in comparison to the non-malignant
oral mucosa tissues. Consistently, high levels of GNA12 protein
expression were detected in 75% of OSCC tissues, while the non-
malignant tissues showed negative or weak expression. We demon-
strated that expression of activated GNA12 (GQ231L) promoted oral
cancer cell migration in a monolayer wound healing assay and cell
invasion through the matrigel barrier, but cell proliferation was
not changed. Correspondingly, exogenous expression of the regula-
tor of G-protein signaling (RGS) blocked G12 family signaling
through RhoA, which resulted in the inhibition of cancer cell migra-
tion and invasion.
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Discussion: In summary, we demonstrated for the ﬁrst time in
OSCC that GNA12 is over-expressed in a large percentage of these
patients and notably, the over-expression drives migration and inva-
sion of oral cancer cells. Taken together, this information indicates
that targeting GNA12 could beneﬁt oral cancer patients by prevent-
ing the spread of the disease.
doi:10.1016/j.oraloncology.2011.06.369
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Oral squamous cell carcinoma (OSCC) is a complex development
process; alcohol and tobacco consumption are the major risk factors
related. erbB receptor family is known to be involved in prolifera-
tion, apoptosis evasion, angiogenesis and lymphnode metastasis of
OSCC. Other molecules involved with this cellular conducts are
ERK, AKT, c-Jun, c-Fos and NF-kb. Identifying molecular biomarkers
and clinical factors that could provide information regarding progno-
sis and treatment is important, however, these biomarkers could had
different conduct depending the risk factor exposed. The aim of this
study was determinate the relationship between 7,12-dimethyl-
benz(a)anthracene (DMBA) and 15% alcohol with the expression of
erbB, ERK, AKT, c-Jun, c-Fos and NF-kb in hyperplasia, dysplasia
and invasive carcinomas developed in hamster buccal pouch carci-
nogenesis model.
Methods: Fifty Syrian golden hamsters were equally divided in
three experimental groups and two control groups. The experimen-
tal groups B and D were painted with 0.5% DMBA solution three
times at week for 14 weeks in right cheek pouch. The experimental
groups C and D consume alcohol at 15% for 14 weeks ad libitum. One
of the control group (A1) remained untreated while another control
(A2) was applied with mineral oil. Tumor frequency, volume, histo-
logical condition, immunohistochemistry, Western Blot and Spear-
man’s correlation test for erbB, erk1/2, AKT, c-Jun, c-Fos and NF-kb
were performed.
Results: Both control groups no present any clinical or histolog-
ical alteration, B and D groups developed dysplasia and invasive well
differentiated (WD) OSCC, since C group showed normal mucosa and
hyperplasia; tumor volume was higher in D group. In similar histo-
logic conditions observe that normal mucosa of C group present in-
crease in erbB2–4, NF-kb, p-ERK, p-AKT than control. Severe
dysplasia of B and D group showed difference in erbB3, c-jun and
p-ERK; the WD OSCC of above groups showed difference in erbB2–
4 and NF-kb. Signiﬁcant correlation was observed to erbB4 and his-
tologic condition (p = 0.039).
Discussion: The expression of erbB2–4 and NF-kb could be asso-
ciated to risk factor exposure. Today many therapies are directed to
erbB inhibition, however, the risk factor associated and the multiple
downstream molecular changes are not considered. If we want
understand the biological conduct of OSCC a more global vision is
necessary.
doi:10.1016/j.oraloncology.2011.06.370
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Introduction: It is well established that a plethora of mutations
that occur in oncogenes and tumor-suppressor genes are the main
drivers of tumorigenesis. The identiﬁcation of these mutations pro-
vides important clues to the cellular processes of carcinogenesis
and affords an opportunity for these genes to be used for diagnostic
and therapeutic purposes. In comparison to cancers such as breast,
lung and colorectal, there is a lack of systematic, large scale charac-
terization of oncogenic mutations oral squamous cell carcinoma
(OSCC).
Materials and methods: This study is a high-throughput analysis
of 238 somatic mutations across 19 oncogenes in 23 OSCC cell lines
and 90 OSCC tissues using the MassARRAY system (Sequenom). The
mutations were further conﬁrmed by direct sequencing.
Results:We identiﬁed 3 mutations (E545K, Q546R and E542K) in
PIK3CA and 1 mutation in HRAS (G13S) in 3/23 cell lines. Likewise,
PIK3CA mutations (H1047R, E545K, E542K) we detected in 6/90 pa-
tients whilst 3/90 patients carried a HRAS mutation (G13S or G12D).
Surprisingly, we did not detect any mutations in the rest of the 17
oncogenes studied here.
Discussion: The results here suggest that PIK3CA and HRAS are
important in the development in a subset of OSCC. Given that
these mutations have been reported to modulate treatment re-
sponse and are correlated with prognosis, this has clinical implica-
tions for our patients. Notably, mutations within the other 17
genes were not detected. Perhaps mutations in these genes are
inherently not present in OSCC or that other mutations besides
the ones examined here could be important for OSCC develop-
ment. Results from this study emphasize the importance of proﬁl-
ing oncogenic mutations in a large pool of OSCC patients as this
information has important clinical implications in the manage-
ment of OSCC patients.
doi:10.1016/j.oraloncology.2011.06.371
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Purpose: As a key component of polycomb-repressive complex 2,
EZH2 represses target genes through histone methylation and is fre-
quently overexpressed and associated with poor prognosis in com-
mon carcinomas. For the ﬁrst time, we reported EZH2 expression
Abstracts / Oral Oncology 47 (2011) S74–S156 S115
